Anand S. Merchant

Anand S. Merchant

Auto-generated profile, based on publicly available information

Anand S. Merchant

NCI, National Institutes of Health

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
NCNadia P. Castro
Nadia P. Castro
MRMaria C. Rangel
Maria C. Rangel
AMAnand S. Merchant
Anand S. Merchant
GMGabriel M MacKinnon
Gabriel M MacKinnon
FCFrank Cuttitta
Frank Cuttitta
YKYoung Kim
Young Kim
Triple-negative breast cancer (TNBC) represents the poorest prognosis among all of breast cancer subtypes with no currently available effective therapy. In this study, we hypothesized that sulforaphane, a dietary component abundant in broccoli and its sprouts, can inhibit malignant cell proliferation and tumor sphere formation of cancer stem-like cells (CSC) in TNBC. CSC population was isolated using FACS analysis with the combined stem cell surface markers, CD44+/CD24−/CD49f+. The effect of sulforaphane on a stem-related embryonic oncogene CRIPTO-1/TDGF1 (CR1) was evaluated via ELISA. In vivo, BalbC/nude mice were supplemented with sulforaphane before and after TNBC cell inoculation (daily intraperitoneal injection of 50 mg sulforaphane/kg for 5 and 3 weeks, respectively), and the effects of sulforaphane during mammary tumor initiation and growth were accessed with NanoString gene analysis. We found that sulforaphane can inhibit cell proliferation and mammosphere formation of CSCs in TNBC. Further analysis of gene expression in these TNBC tumor cells revealed that sulforaphane significantly decreases the expression of cancer-specific CR1, CRIPTO-3/TDGF1P3 (CR3, a homologue of CR1), and various stem cell markers including Nanog, aldehyde dehydrogenase 1A1 (ALDH1A1), Wnt3, and Notch4. Our results suggest that sulforaphane may control the malignant proliferation of CSCs in TNBC via Cripto-mediated pathway by either suppressing its expression and/or by inhibiting Cripto/Alk4 protein complex formation. Thus, the use of sulforaphane for chemoprevention of TNBC is plausible and warrants further clinical evaluation.

7 April 2020 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JSJae Young So
Jae Young So
NSNicolas Skrypek
Nicolas Skrypek
HYHOWARD H YANG
HOWARD H YANG
AMAnand S. Merchant
Anand S. Merchant
GNGeorge W. Nelson
George W. Nelson
YLYang Li
Yang Li
Current cancer treatments are largely based on the genetic characterization of primary tumors and are ineffective for metastatic disease. Here we report that DNA methyltransferase 3B (DNMT3B) is induced at distant metastatic sites and mediates epigenetic reprogramming of metastatic tumor cells. Multi-omics analysis and spontaneous metastatic mouse models revealed that DNMT3B alters multiple pathways including STAT3, NFκB, PI3K/Akt, β-catenin, and Notch signaling, which are critical for cancer cell survival, apoptosis, proliferation, invasion, and colonization. PGE2 and IL-6 were identified as critical inflammatory mediators in DNMT3B induction. DNMT3B expression levels positively correlated with human metastatic progression. Targeting IL-6 or COX-2 reduced DNMT3B induction and improved chemo- or PD1- therapy. We propose a novel mechanism linking the metastatic microenvironment with epigenetic alterations that occur at distant sites. These results caution against the "Achilles' heel" in cancer therapies based on primary tumor characterization and suggests targeting DNMT3B induction as new option for treating metastatic disease.

3 April 2023
Verified
Other
Open access
NCNadia P. Castro
Nadia P. Castro
MRMaria C. Rangel
Maria C. Rangel
AMAnand S. Merchant
Anand S. Merchant
GMGabriel MacKinnon
Gabriel MacKinnon
FCFrank Cuttitta
Frank Cuttitta
YKYoung S. Kim
Young S. Kim

3 April 2023
Verified
Other
Open access
NCNadia P. Castro
Nadia P. Castro
MRMaria C. Rangel
Maria C. Rangel
AMAnand S. Merchant
Anand S. Merchant
GMGabriel MacKinnon
Gabriel MacKinnon
FCFrank Cuttitta
Frank Cuttitta
YKYoung S. Kim
Young S. Kim
NanoString nCounter® Stem Cell Gene Expression Codeset showing differentially expressed genes (p < 0.05) between control and sulforaphane-treated groups during primary tumor growth

3 April 2023
Verified
Other
Open access
NCNadia P. Castro
Nadia P. Castro
MRMaria C. Rangel
Maria C. Rangel
AMAnand S. Merchant
Anand S. Merchant
GMGabriel MacKinnon
Gabriel MacKinnon
FCFrank Cuttitta
Frank Cuttitta
YKYoung S. Kim
Young S. Kim
Embryonic stem cell and EMT-MET markers selected for the nCounter® Customized Gene Expression Codeset showing differentially expressed genes (p < 0.05) between CTRLs and SFN-treated groups during primary tumor growth

3 April 2023
Verified
Other
Open access
NCNadia P. Castro
Nadia P. Castro
MRMaria C. Rangel
Maria C. Rangel
AMAnand S. Merchant
Anand S. Merchant
GMGabriel MacKinnon
Gabriel MacKinnon
FCFrank Cuttitta
Frank Cuttitta
YKYoung S. Kim
Young S. Kim
SFN modulates CR1 promoter luciferase activity in MDA-MB-231-Luc-D3H1 cells.